Overview

A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects

Status:
Completed

Trial end date:
2011-04-01

Target enrollment:

Participant gender:

Summary

This is a single and multiple dose study in healthy male and female (of non-childbearing potential) Japanese volunteers, to assess the safety, tolerability, and blood and urine drug levels of intravenous (IV) NXL104 alone and when given in combination with ceftazidime.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca
Pfizer

Treatments:

Avibactam
Ceftazidime